苏州近岸蛋白质科技股份有限公司 融资与对外担保管理制度 二〇二五年十一月 苏州近岸蛋白质科技股份有限公司 融资与对外担保管理制度 第一章 总则 第一条 为了规范苏州近岸蛋白质科技股份有限公司（以下简称"公司"） 的融资与对外担保行为，有效控制公司融资风险和担保风险，保护公司财务安全 和投资者的合法权益，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民共和国民 法典》（以下简称"《民法典》"）等有关法律法规、规范性文件及《苏州近岸 蛋白质科技股份有限公司章程》（以下简称"《公司章程》"）之规定，并结合 公司实际情况，特制订本制度。 第二条 本制度所称融资，是指公司向以银行为主的金融机构进行间接融资 的行为，主要包括综合授信、流动资金贷款、固定资产贷款、信用证融资、票据 融资和开具保函等形式。 公司直接融资行为不适用本制度。 第三条 本制度所称对外担保，是指公司以第三人身份为他人提供保证、抵 押、质押或其他形式的担保。当他人不履行债务时，由公司按照约定履行债务或 者承担责任的行为。 (一)拟提供融资的金融机构名称； 第四条 公司为自身债务提供 ...

苏州近岸蛋白质科技股份有限公司 2025 年第二次临时股东大会会议资料 证券代码：688137 证券简称：近岸蛋白 苏州近岸蛋白质科技股份有限公司 2025 年第二次临时股东大会 会议资料 2025 年 12 月 苏州近岸蛋白质科技股份有限公司 2025 年第二次临时股东大会会议资料 | | | | 2025 | 年第二次临时股东大会会议须知 | 1 | | | --- | --- | --- | --- | | 2025 | 年第二次临时股东大会会议议程 | 3 | | | | 议案一 | 关于取消监事会并修订《公司章程》的议案 | 5 | | | 议案二 | 关于提请股东大会修订公司部分治理制度的议案 | 7 | 苏州近岸蛋白质科技股份有限公司 2025 年第二次临时股东大会会议资料 2025 年第二次临时股东大会会议须知 为维护广大投资者的合法权益，保障股东在本次股东大会期间依法行使权利， 根据《中华人民共和国公司法》《中华人民共和国证券法》、中国证券监督管理 委员会《上市公司股东会规则》和公司《股东会议事规则》等有关规定，特制定 本会议须知： 一、公司负责本次股东大会的议程安排和会务工作,为确认出席大 ...

Market Overview - The biopharmaceutical sector experienced a decline of 1.72% on December 2, with Aopumai leading the drop [1] - The Shanghai Composite Index closed at 3897.71, down 0.42%, while the Shenzhen Component Index closed at 13056.7, down 0.68% [1] Individual Stock Performance - Dongbao Bio (300239) closed at 5.80, up 1.05% with a trading volume of 93,700 shares and a transaction value of 53.99 million yuan [1] - Aopumai (688293) saw a significant drop of 8.01%, closing at 50.32 with a trading volume of 33,400 shares and a transaction value of 171 million yuan [2] - Other notable declines included Kanghong Pharmaceutical (002773) down 3.78% and Watson Bio (300142) down 3.17% [2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 456 million yuan from institutional investors, while retail investors saw a net inflow of 270 million yuan [2] - Notable stocks with significant capital inflows included He Yuan Bio (688765) with a net inflow of 17.69 million yuan from institutional investors [3] - Conversely, stocks like Rongchang Bio (688331) and Shenzhou Cell (688520) also saw mixed capital flows, indicating varied investor sentiment [3]

近岸蛋白首次公开发行股票的发行费用总额为12,078.67万元，其中保荐机构民生证券股份有限公司 获得承销保荐费用9,842.17万元。 （责任编辑：华青剑） 中国经济网北京12月2日讯 近岸蛋白(688137.SH)今日收报40.62元，跌幅3.52%。目前该股处于破发 状态。 近岸蛋白于2022年9月29日在上交所科创板上市，发行价格为106.19元/股，发行股票数量为 1,754.3860万股，保荐人（主承销商）为民生证券股份有限公司（现为"国联民生证券股份有限公 司"），保荐代表人为王璐、黄立超。 近岸蛋白首次公开发行股票募集资金总额为186,298.25万元，扣除发行费用后募集资金净额为 174,219.58万元。该公司最终募集资金净额较原计划多24,219.58万元。近岸蛋白于2022年9月26日披露的 招股说明书显示，其拟募集资金150,000.00万元，拟分别用于诊断核心原料及创新诊断试剂产业化项 目、研发中心建设项目和补充流动资金。 ...

证券代码：688137 证券简称：近岸蛋白 公告编号：2025-055 苏州近岸蛋白质科技股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司于 2025 年 10 月 13 日召开第二届董事会第十三次临时会议，审议通过了 《关于延长股份回购期限的议案》，同意公司原回购实施期限延长 6 个月，延期至 2026 年 4 月 13 日止，除回购实施期限延长外，公司回购股份方案的其他内容未发 生变化。具体内容详见公司于 2025 年 10 月 14 日在上海证券交易所网站 （www.sse.com.cn）披露的《苏州近岸蛋白质科技股份有限公司关于延长股份回 购实施期限的公告》（公告编号：2025-041） 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司在回购股份期间，应当在每个月的前 3 个交 易日内公告截至上月末的回购进展情况。现将公司回购股份进展情况公告如下： 截至 2025 年 11 月 30 日，公司暂未开展 ...

近岸蛋白公告称，公司于2024年10月15日股东大会审议通过回购方案，拟以1000万元-2000万元自有资 金回购股份，用于减少注册资本，回购价不超30.68元/股，原回购期限至2025年10月15日。2025年10月 13日，公司决定将回购期限延长6个月至2026年4月13日。截至2025年11月30日，公司暂未开展股票回 购，后续将择机实施。 ...

Group 1 - The core point of the announcement is that shareholders holding less than 5% of the company's shares plan to reduce their holdings due to operational and funding needs, with a reduction period starting three trading days after the announcement and lasting for three months [2][3]. - The shareholders involved in the reduction are Nanjing Jinli Venture Capital Partnership, Suzhou Jinling Venture Capital Partnership, and Shanghai Pujin Technology Development Partnership, collectively holding 140,111 shares, which is approximately 0.1997% of the total share capital [2]. - The reduction will be executed through methods such as centralized bidding and block trading, with the selling price determined by market conditions [2][3]. Group 2 - The shareholders have made commitments regarding their shareholding intentions and reduction plans, ensuring compliance with relevant laws and regulations, including a three-day prior notice before any reduction [3]. - The company confirms that the reduction plan will not lead to a change in control of the company and is consistent with previously disclosed commitments [4]. - The announcement emphasizes that the reduction plan aligns with the regulations set forth by the Shanghai Stock Exchange and other relevant authorities, ensuring that the shareholders will fulfill their disclosure obligations during the reduction period [4].

股东南京金溧创业投资合伙企业（有限合伙）（以下简称"南京金溧"）和 苏州金灵创业投资合伙企业（有限合伙）（以下简称"苏州金灵"）为一致行动 人关系，共计持有公司 29,111 股股份，合计占公司总股本比例为 0.0415%；股 东上海普近科技发展合伙企业（有限合伙）（以下简称"上海普近"）持有公司 111,000 股股份，占公司总股本比例为 0.1582%。 减持计划的主要内容 南京金溧、苏州金灵和上海普近因自身经营发展和资金需求计划拟通过集中 竞价、大宗交易等方式减持所持有的公司部分股份，股东的减持价格按照市场价 格确定，减持期间为自本公告披露之日起 3 个交易日后的三个月内。 相关股东均为持股 5%以下股东，均不属于公司控股股东、实际控制人或董 监高，本次披露减持计划为履行在招股说明书中载明的减持公司股份将提前 3 个交易日公告的承诺。 在上述股东减持期间，若有送股、资本公积转增股本、配股等股份变动事项， 则应对减持数量进行相应调整。 证券代码：688137 证券简称：近岸蛋白 公告编号：2025-054 苏州近岸蛋白质科技股份有限公司 关于持股 5%以下股东减持股份计划公告 本公司董事会、全体董事及相关 ...

Summary of Key Points Core Viewpoint - On November 27, several A-share listed companies disclosed their shareholding changes, with notable increases in holdings from some companies and reductions from others, indicating varying levels of confidence among stakeholders in the market [1]. Group 1: Shareholding Increases - Mindray Medical's actual controller and chairman, Li Xiting, plans to increase his stake in the company by 200 million yuan [2]. - Everbright Bank saw Citic Financial Assets increase its holdings in both A-shares and H-shares by a total of 1% from July 24 to November 27 [2]. - MaiDe Medical's chairman and actual controller, Lin Junhua, proposed a share buyback plan ranging from 20 million to 40 million yuan [2]. Group 2: Shareholding Reductions - Yonghe Intelligent Control's shareholders plan to collectively reduce their holdings by no more than 3.29% [2]. - Perfect World’s actual controller, Chi Yufeng, intends to reduce his stake by no more than 1.70% [2]. - XueNeng Technology's shareholder, Shanghang Xingyuan, plans to reduce holdings by no more than 1.6816% [2]. - Hongxiang New Materials' controlling shareholder, Hongbo Chemical, has cumulatively reduced its stake by 3% recently [2]. - Nearshore Protein's shareholders plan to collectively reduce their holdings by no more than 0.1997% [2]. - Aerospace Hongtu's director and executive, Huang Yongbo, plans to reduce his stake by no more than 0.0019% [2]. - Yidelong's shareholder, Wang Ming, intends to reduce his holdings by no more than 2% [2]. - Zhongman Petroleum's shareholders plan to collectively reduce their holdings by no more than 3% [2]. - Innovation New Materials' shareholder, Hualian Group, plans to reduce its stake by no more than 1% [2]. - Saiwei Electronics has seen the National Integrated Circuit Industry Investment Fund reduce its holdings by 6.4278 million shares [2]. - Zhongzhi Technology's shareholder, Zhongzhi Investment, plans to reduce its stake by no more than 0.76% [2]. - Jiangsu Boyun's shareholder, Lansan Venture Capital, intends to reduce its holdings by no more than 1% [2]. - Huasheng Lithium's deputy general manager, Zhang Conghe, plans to reduce his stake by no more than 0.31% [2]. - Huasheng Electric's shareholder, Dunxing Jucai, reduced its holdings by 444,500 shares between November 25 and 27 [2]. - Matrix Technology's shareholder, Li Jun, plans to reduce his stake by no more than 0.22% [2].

Core Points - The company Nearshore Protein announced on November 27 that its shareholders plan to reduce their holdings starting from December 4, 2025, over a period of three months [1] Shareholder Reduction Plans - Nanjing Jinli Venture Capital Partnership intends to reduce its holdings by no more than 13,700 shares, representing 0.0196% of the company's total share capital [1] - Suzhou Jinling Venture Capital Partnership plans to reduce its holdings by no more than 15,400 shares, accounting for 0.0219% of the total share capital [1] - Shanghai Pujin Technology Development Partnership aims to reduce its holdings by no more than 111,000 shares, which is 0.1582% of the total share capital [1] - The reduction prices will be determined based on market conditions, and the reason for the reduction is stated as the shareholders' own operational development needs [1]